Zevra Therapeutics (NASDAQ:ZVRA) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 price objective on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $1.45 EPS and FY2027 earnings at $2.55 EPS.

A number of other equities research analysts have also issued reports on ZVRA. Maxim Group upped their price objective on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a buy rating in a report on Tuesday, April 2nd. William Blair reissued an outperform rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $19.50.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $6.11 on Tuesday. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $7.28. The firm has a market capitalization of $255.72 million, a price-to-earnings ratio of -4.53 and a beta of 1.97. The company has a fifty day simple moving average of $4.74 and a 200-day simple moving average of $5.41. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.88.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. The business had revenue of $3.43 million during the quarter, compared to analyst estimates of $3.52 million. On average, equities analysts anticipate that Zevra Therapeutics will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after buying an additional 58,866 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in Zevra Therapeutics by 1.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after buying an additional 9,062 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its position in Zevra Therapeutics by 11.0% in the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock valued at $2,495,000 after buying an additional 42,766 shares during the last quarter. Armistice Capital LLC acquired a new position in Zevra Therapeutics in the fourth quarter valued at about $1,755,000. Finally, Mystic Asset Management Inc. lifted its position in Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after buying an additional 35,514 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.